AbbVie Inc. $ABBV is Tsfg LLC’s 4th Largest Position

Tsfg LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 123,432 shares of the company’s stock after purchasing an additional 3,250 shares during the period. AbbVie comprises about 4.5% of Tsfg LLC’s investment portfolio, making the stock its 4th biggest position. Tsfg LLC’s holdings in AbbVie were worth $28,580,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Conning Inc. raised its position in AbbVie by 7.1% in the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after buying an additional 12,690 shares during the last quarter. Diversified Trust Co grew its position in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares during the period. Dohj LLC raised its stake in AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after buying an additional 1,335 shares during the last quarter. Permanent Capital Management LP bought a new position in shares of AbbVie during the 3rd quarter valued at $720,000. Finally, Railway Pension Investments Ltd boosted its stake in shares of AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after buying an additional 211,800 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Citigroup reduced their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. Finally, Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $251.17.

AbbVie Trading Up 1.2%

NYSE ABBV opened at $225.76 on Tuesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market cap of $399.01 billion, a price-to-earnings ratio of 171.03, a PEG ratio of 0.92 and a beta of 0.35. The company’s 50 day moving average is $224.33 and its two-hundred day moving average is $218.90.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the company posted $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.